Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM
3.18 | 0.05 (1.60%) |
| Exchange : | NASDAQ (US Dollar) |
| Ric Code : | ORMP |
| Volume : | 19,807 |
| Date : | 10-23-2019 |
* Minimum 20 minute delay See terms
–
Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.
Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive [...]
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
Topline data readout expected Q4 2019 NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the [...]
Oramed to Present at Three Upcoming Conferences
NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three [...]
Oramed to Present at World Diabetes Congress
NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific [...]
Investors Tools